Form 4: Oncology Institute CEO Forfeits Shares After Performance Targets Missed

Oncology Institute's CEO, Daniel Virnich, forfeited a total of 195,236 unvested restricted shares due to the company's stock price failing to meet specific performance targets.

Summary

• Daniel Virnich, CEO of Oncology Institute, forfeited 78,094 shares of common stock due to the company's stock price not reaching $12.50 for 20 days within a 30-day period.
• An additional 117,142 shares were forfeited because the stock price did not reach $15.00 for 20 days within a 30-day period.
• These forfeitures are related to earn-out targets set after the closing of the Business Combination on November 12, 2021.
• The forfeitures occurred on November 12, 2024, and the shares were unvested and subject to continued employment.
• Following these transactions, Mr. Virnich directly owns 721,711 shares of common stock.

Sentiment

Score: 3

Explanation: The document indicates a failure to meet performance targets, leading to share forfeitures, which is a negative signal for investors.

Negatives

• The CEO forfeited a significant number of shares due to the company's stock price not meeting performance targets.
• The failure to meet the stock price targets suggests potential underperformance relative to the goals set during the Business Combination.

Risks

• The failure to meet stock price targets may indicate challenges in the company's performance or market perception.
• The forfeiture of shares by the CEO could negatively impact investor confidence.

Industry Context

This type of share forfeiture is not uncommon when performance targets are not met, particularly in companies that have recently undergone a business combination or merger. It highlights the importance of achieving specific milestones for management to realize the full value of their equity compensation.

Comparison to Industry Standards

• Share forfeiture clauses are common in executive compensation packages, particularly in growth-oriented companies.
• The specific targets of $12.50 and $15.00 per share are unique to this agreement and would need to be compared to similar agreements in the healthcare or oncology sector to determine if they are standard or aggressive.
• Companies like Exact Sciences or Guardant Health, which are also in the oncology space, may have similar performance-based compensation structures, but the specific details would vary.

Stakeholder Impact

• Shareholders may view the share forfeiture negatively, potentially impacting the stock price.
• Employees may be concerned about the company's performance and future prospects.

Key Dates

Keywords

Oncology Institute, stock forfeiture, CEO, Daniel Virnich, performance targets, earn-out shares, stock price, Business Combination